D.E. Shaw & Co
BEAM icon

D.E. Shaw & Co’s Beam Therapeutics BEAM Stock Holding History

D.E. Shaw & Co’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-20,000
Closed -$1.6M – 4749
2021
Q1 		$1.6M Buy
+20,000
New +$1.9M ﹤0.01% 2773

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

D.E. Shaw & Co's BEAM Position: Q2 2026 in Review

D.E. Shaw & Co opened a new position in Beam Therapeutics (BEAM) in Q2 2026: 130,577 shares worth $4.48M. The stake represents ﹤0.01% of the portfolio and ranks #2494 among its holdings. This is a return to the name: D.E. Shaw & Co previously reported a position in BEAM as recently as Q4 2025.

D.E. Shaw & Co first reported a position in BEAM in Q1 2021 and has held it in 7 quarters since. The position peaked at $5.16M in Q3 2021. 278 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

  • D.E. Shaw & Co held 130,577 shares of Beam Therapeutics worth $4.48M as of Q2 2026.
  • Beam Therapeutics was a new D.E. Shaw & Co position in Q2 2026.
  • Beam Therapeutics made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q2 2026, its #2494 holding.
  • D.E. Shaw & Co first reported a position in Beam Therapeutics in Q1 2021 and has held it in 7 quarters since.
  • D.E. Shaw & Co's Beam Therapeutics position peaked at $5.16M in Q3 2021.
  • 278 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.